SCHEMBL3064995

SCHEMBL3064995

NCCc1c[n+]([O-])c(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 3/20 0.34
SNCA P37840 1/20 0.34
TAAR1 Q96RJ0 2/20 0.33
ALDH1A1 P00352 3/20 0.32
CYP3A4 P08684 2/20 0.32
TSHR P16473 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
MAPK1 P28482 1/20 0.32
ALOX15 P16050 1/20 0.32
PDE7A Q13946 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.31
GPR35 Q9HC97 1/20 0.31
GRIA2 P42262 1/20 0.31
MEN1 O00255 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372861 0.75 VCAM1 (0.44) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL3060390 0.74 VCAM1 (0.46) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL5149992 0.73 MAPK1 (0.52) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL29671003 0.71 TSHR (0.42) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL624089 0.71 TSHR (0.42) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL28980003 0.71 VCAM1 (0.39) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL3070950 0.69 TSHR (0.55) VCAM1ALDH1A1TSHRTDP1MAPK1
SCHEMBL11597123 0.68 CYP1A2 (0.60) ALDH1A1CYP3A4TSHRTDP1MAPK1
SCHEMBL693936 0.68 MAPT (0.40) VCAM1ALDH1A1CYP3A4TSHRTDP1
SCHEMBL17138368 0.68 SNCA (0.67) SNCAALDH1A1CYP3A4TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368342-B3 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORP (US) 2010-12-01 EP disclosed
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2010-10-21 US disclosed
US-7642267-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2010-01-05 US disclosed
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2008-09-18 US disclosed
US-7300945-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2007-11-27 US disclosed
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION 2006-02-02 US disclosed
EP-1368342-B1 BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS NEUROGEN CORP (US) 2005-09-07 EP disclosed
US-6916819-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2005-07-12 US disclosed
US-20030069257-A1 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 VCAM1 2303/4885SNCA 1660/4885TAAR1 321/4885
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 VCAM1 2303/4885SNCA 1660/4885TAAR1 321/4885
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives GABBR1, GABBR2, GABRA2 VCAM1 2303/4885SNCA 1660/4885TAAR1 321/4885
US-20030069257-A1 Benzimidazole and pyridylimidazole derivatives GABBR1, GABRA1, GABBR2 VCAM1 2076/4885SNCA 1081/4885TAAR1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.